⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL27607763 | 0.98 | — | — | |
| SCHEMBL27675505 | 0.84 | — | — | |
| SCHEMBL6906143 | 0.72 | — | — | |
| SCHEMBL12570744 | 0.72 | — | — | |
| SCHEMBL5884619 | 0.72 | — | — | |
| SCHEMBL24667243 | 0.70 | — | — | |
| SCHEMBL29765179 | 0.70 | — | — | |
| SCHEMBL22308091 | 0.70 | — | — | |
| SCHEMBL27724806 | 0.70 | — | — | |
| SCHEMBL4650148 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305139-A | Toxoflavin haptens, artificial antigen, antibody and its synthetic method and application | 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） | 2019-10-08 | — | — | CN | claimed |
| CN-104130250-B | Deuterated dasatinib and preparation method and application thereof | 郑州泰基鸿诺药物科技有限公司 | 2016-06-22 | — | — | CN | claimed |
| CN-104130250-A | deuterated dasatinib and preparation method and application thereof | TETRANOV BIOPHARM INC | 2014-11-05 | — | — | CN | claimed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-109195975-B | Diazaspiro [5.5] undecane derivative and application thereof | 四川海思科制药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-110305139-A | Toxoflavin haptens, artificial antigen, antibody and its synthetic method and application | 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） | 2019-10-08 | — | — | CN | disclosed |
| CN-109942556-A | Pyrimidinone compound and its application | 上海青煜医药科技有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-109195975-A | Diazaspiro [5.5] undecane derivative and application thereof | 四川海思科制药有限公司 | 2019-01-11 | — | — | CN | disclosed |
| CN-104130250-B | Deuterated dasatinib and preparation method and application thereof | 郑州泰基鸿诺药物科技有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-103038230-B | Aminopyrimidine derivatives as LRRK2 modulators | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-25 | — | — | CN | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| CN-101896481-A | Pyrimidyl indoline compound | DAIICHI SANKYO CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101528702-A | Quinoline compounds and methods of use | ARRAY BIOPHARMA INC (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |